Zacks Research Boosts Earnings Estimates for Haemonetics

Haemonetics Corporation (NYSE:HAE) – Investment analysts at Zacks Research upped their FY2026 EPS estimates for shares of Haemonetics in a note issued to investors on Tuesday, February 24th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings of $4.95 per share for the year, up from their previous estimate of $4.93. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2026 earnings at $1.27 EPS, Q2 2027 earnings at $1.37 EPS, Q4 2027 earnings at $1.37 EPS, FY2027 earnings at $5.34 EPS, Q2 2028 earnings at $1.46 EPS and Q3 2028 earnings at $1.51 EPS.

A number of other brokerages also recently commented on HAE. Barrington Research set a $94.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Haemonetics in a research note on Monday, December 29th. Mizuho dropped their price target on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a research note on Friday, February 6th. BTIG Research reissued a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. Finally, Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.44.

Haemonetics Price Performance

Shares of HAE opened at $62.37 on Wednesday. The business’s 50-day moving average is $70.83 and its 200-day moving average is $63.97. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. The company has a market capitalization of $2.90 billion, a price-to-earnings ratio of 17.18, a P/E/G ratio of 1.29 and a beta of 0.28. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $87.32.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The company had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. During the same quarter in the prior year, the company earned $1.19 earnings per share. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Kemnay Advisory Services Inc. bought a new stake in Haemonetics during the fourth quarter worth approximately $26,000. True Wealth Design LLC lifted its stake in shares of Haemonetics by 6,700.0% in the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 335 shares during the last quarter. Leonteq Securities AG bought a new stake in shares of Haemonetics during the 4th quarter worth $30,000. EverSource Wealth Advisors LLC grew its stake in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 396 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new position in Haemonetics in the 4th quarter worth $34,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.